What Is a Logical Approach for Choosing Among New Agents for Patients With Type 2 Diabetes?

摘要

Approximately two-thirds of US adults are now obese or overweight, predisposing to the development of type 2 diabetes, which is now estimated to affect 8% of the adult population, with another 3% undiagnosed.1 As such, this has been an area of active drug development.Many recently approved medications target the incretin system. These include glucagon-like peptide 1 (GLP-1) receptor agonists, an amylin mimetic, and dipeptidyl-peptidase IV (DPP-4) inhibitors. New insulin analogues allow for more physiologic insulin regimens to attain tighter glycemic control with lower rates of hypoglycemia. Meglitinides, a bile acid se-questrant, and a dopamine-2 agonist are also available for selected patients with type 2 diabetes.